Search results
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
Zacks via Yahoo Finance· 5 months agoBiogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU...
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
Zacks via Yahoo Finance· 1 year agoBiogen BIIB announced that the European Medicines Agency (EMA) has accepted the marketing...
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects
Zacks via Yahoo Finance· 1 year agoDetailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the...
Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the favorable return generated for...
Simply Wall St. via Yahoo Finance· 11 months agoThe simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right...
Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year
Simply Wall St. via Yahoo Finance· 1 year agoPassive investing in index funds can generate returns that roughly match the overall market. But you...
Do Its Financials Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?
Simply Wall St. via Yahoo Finance· 11 months agoBiogen's (NASDAQ:BIIB) stock is up by a considerable 14% over the past three months. We wonder if...
What's in Store for Biogen (BIIB) This Earnings Season?
Zacks via Yahoo Finance· 4 weeks agoBiogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its...
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
Zacks via Yahoo Finance· 2 years agoBiogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is...
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
Zacks via Yahoo Finance· 6 months agoBiogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its...
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
Zacks via Yahoo Finance· 2 years agoMost of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are...